Asset Publisher

Draft Genetic Testing Policies

Effective for dates of service on or after March 17, 2024, the changes listed in the document below will apply to Carelon Genetic Testing Clinical Appropriateness Guidelines. As part of the Carelon guidelines semi-annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.

Summary of Changes to Carelon Genetic Testing Clinical Appropriateness Guidelines Effective March 17, 2024

To continue to the Carelon website to view genetic testing policies, click "Accept” below.

Comment on Draft Policies

To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage. 

Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration.

Comments are accepted for 45 days from the posting date listed on the draft

Make sure your voice is heard by providing feedback directly to us:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878